BMS is a New York-based biopharmaceutical firm that develops and commercializes medicines for treating patients prevail over serious diseases.
Read moreAnnual Revenue
$47B
BMS's revenue is the ranked 9th among it's top 10 competitors. The top 10 competitors average 42.6B. Over the last four quarters, BMS's revenue has decreased by $-55000000. Specifically, in Q1 2022's revenue was $11.6B; in Q4 2021, it was $12B; in Q3 2021, it was $11.6B; in Q2 2021, BMS's revenue was $11.7B.